Last reviewed · How we verify
NCT03652870: ADepT-PD
Antidepressants Trial in Parkinson's Disease
Phase 3 trial testing Nortriptyline in Depression in 52 participants. Completed in 30 April 2023.
23 January 2023
Quick facts
| Lead sponsor | University College, London |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 52 |
| Start date | 5 March 2021 |
| Primary completion | 23 January 2023 |
| Estimated completion | 30 April 2023 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Nortriptyline (NORTRIPTYLINE) — full drug profile →
- Escitalopram (escitalopram) — full drug profile →
- Placebo
Conditions studied
- Depression — all drugs for Depression →
- Parkinson Disease — all drugs for Parkinson Disease →
Sponsor
University College, London
Who can join
18 and older, any sex, with Depression or Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomised trial in a NHS setting, comparing the clinical effectiveness and cost-effectiveness of the selective serotonin reuptake inhibitor, escitalopram, and of the tricyclic antidepressant, nortriptyline, to placebo, undertaken in a real-life setting in addition to standard psychological care for the treatment of patients with depression in Parkinson's disease. Participants will be randomly allocated 1:1:1 to receive escitalopram or nortriptyline or placebo.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
The neuropsychiatry of Parkinson's disease: advances and challenges.
Weintraub D, Aarsland D, Chaudhuri KR, Dobkin RD, et al · · 2022 · cited 288× · PMID 34942142 · DOI 10.1016/s1474-4422(21)00330-6 -
Computer vision quantification of whole-body Parkinsonian bradykinesia using a large multi-site population.
Morinan G, Dushin Y, Sarapata G, Rupprechter S, et al · · 2023 · cited 31× · PMID 36707523 · DOI 10.1038/s41531-023-00454-8 -
Parkinson's disease therapy: what lies ahead?
Wolff A, Schumacher NU, Pürner D, Machetanz G, et al · · 2023 · cited 19× · PMID 37147404 · DOI 10.1007/s00702-023-02641-6 -
Targeting 5-HT Is a Potential Therapeutic Strategy for Neurodegenerative Diseases.
Xing C, Chen H, Bi W, Lei T, et al · · 2024 · cited 8× · PMID 39769209 · DOI 10.3390/ijms252413446 -
Antidepressants Trial in Parkinson's Disease (ADepT-PD): protocol for a randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline on depressive symptoms in Parkinson's disease.
Schrag A, Carroll C, Duncan G, Molloy S, et al · · 2022 · cited 6× · PMID 36510237 · DOI 10.1186/s12883-022-02988-5 -
Placebo-controlled three-armed pilot trial of Escitalopram or Nortriptyline for depressive symptoms in Parkinson's disease (ADepT-PD).
Schrag A, Embleton-Thirsk A, Carroll C, Serfaty M, et al · · 2026 · PMID 42101650 · DOI 10.1007/s00702-026-03170-8 -
Effectiveness of Escitalopram and Nortriptyline on Depressive Symptoms in Parkinson's disease: the ADepT-PD RCT pilot.
Schrag A, Carroll C, Lewis G, Serfaty M, et al · · 2025 · PMID 41217862 · DOI 10.3310/hfdo7575
Verify or expand the search:
- PubMed search for NCT03652870
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Nortriptyline
Trials testing the same drug.
- NCT04226365 — Pediatric Concussion Outcomes · Phase 4 · terminated
- NCT03844412 — Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments · Phase 2 · completed
- NCT03652571 — Nortriptyline for the Treatment of Functional Dyspepsia · Phase 3 · terminated
- NCT00009672 — Pain Treatment for Sciatica · Phase 2 · completed
Other recruiting trials for Depression
Currently open trials in the same condition.
- NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or · Phase 2 · recruiting
- NCT06906939 — A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression · EARLY_PHASE1 · recruiting
- NCT07517549 — Sexual Health Education During Pregnancy · NA · recruiting
- NCT06408246 — ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression · Phase 2 · recruiting
- NCT07449676 — Effects of an Innovative TCM-based Tui Jing Therapy on Psychological and Neurophysiological Functions in Depression · NA · recruiting
Other University College, London trials
Trials by the same sponsor.
- NCT07386652 — Intensive Comprehensive Aphasia Programme for People With Post-Stroke Aphasia · NA · not yet recruiting
- NCT06924086 — The Children's Adaptive Deep Brain Stimulation for Epilepsy Trial · NA · recruiting
- NCT07386678 — Study of Imaging and Molecular Biomarkers in Uncomplicated Rhegmatogenous Retinal Detachment · not yet recruiting
- NCT07414940 — ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium · Phase 1, PHASE2 · not yet recruiting
- NCT07214454 — TCDS for the Treatment of Chronic Migraine · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03652870 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University College, London
- Last refreshed: 6 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03652870.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing